106 related articles for article (PubMed ID: 9155162)
1. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
Funato T
Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
[TBL] [Abstract][Full Text] [Related]
2. [Reversal of drug resistance in human cancer cells by anti-oncogenes].
Funato T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic applications of ribozymes.
Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
[TBL] [Abstract][Full Text] [Related]
4. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
Kobayashi H; Takemura Y; Miyachi H
Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
[TBL] [Abstract][Full Text] [Related]
6. [Circumventing drug resistance in human tumors by antisense ribozyme].
Funato T
Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
Kaszubiak A; Holm PS; Lage H
Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
9. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
Nagata J; Kijima H; Hatanaka H; Asai S; Miyachi H; Abe Y; Yamazaki H; Nakamura M; Watanabe N; Mine T; Kondo T; Scanlon KJ; Ueyama Y
Int J Oncol; 2002 Nov; 21(5):1021-6. PubMed ID: 12370750
[TBL] [Abstract][Full Text] [Related]
10. The application of ribozymes to HIV infection.
Rossi JJ
Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
12. Ribozyme: a clinical tool.
Khan AU
Clin Chim Acta; 2006 May; 367(1-2):20-7. PubMed ID: 16426595
[TBL] [Abstract][Full Text] [Related]
13. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA.
Nosrati M; Li S; Bagheri S; Ginzinger D; Blackburn EH; Debs RJ; Kashani-Sabet M
Clin Cancer Res; 2004 Aug; 10(15):4983-90. PubMed ID: 15297398
[TBL] [Abstract][Full Text] [Related]
15. Ribozymes: applications to functional analysis and gene discovery.
Shiota M; Sano M; Miyagishi M; Taira K
J Biochem; 2004 Aug; 136(2):133-47. PubMed ID: 15496583
[TBL] [Abstract][Full Text] [Related]
16. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
Shore SK; Nabissa PM; Reddy EP
Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
[TBL] [Abstract][Full Text] [Related]
18. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.
Kobayashi H; Dorai T; Holland JF; Ohnuma T
Cancer Res; 1994 Mar; 54(5):1271-5. PubMed ID: 8118816
[TBL] [Abstract][Full Text] [Related]
19. Allosterically controllable maxizymes for molecular gene therapy.
Iyo M; Kawasaki H; Taira K
Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
[TBL] [Abstract][Full Text] [Related]
20. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
Li YL; Torchet C; Vergne J; Maurel MC
Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
